Pointstate Capital LP Lifted Pacira Pharmaceuticals (PCRX) Position By $2.39 Million; Endeavour Silver Ordinary Shares (cana (EXK) Shorts Down By 9.11%

April 17, 2018 - By Steve Bissell

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Endeavour Silver Corporation Ordinary Shares (cana (NYSE:EXK) had a decrease of 9.11% in short interest. EXK’s SI was 5.42 million shares in April as released by FINRA. Its down 9.11% from 5.96M shares previously. With 1.34 million avg volume, 4 days are for Endeavour Silver Corporation Ordinary Shares (cana (NYSE:EXK)’s short sellers to cover EXK’s short positions. The SI to Endeavour Silver Corporation Ordinary Shares (cana’s float is 4.3%. The stock increased 5.32% or $0.15 during the last trading session, reaching $2.97. About 1.65 million shares traded or 25.33% up from the average. Endeavour Silver Corp. (NYSE:EXK) has declined 22.96% since April 17, 2017 and is downtrending. It has underperformed by 34.51% the S&P500.

Pointstate Capital Lp increased Pacira Pharmaceuticals Inc (PCRX) stake by 4.67% reported in 2017Q4 SEC filing. Pointstate Capital Lp acquired 53,107 shares as Pacira Pharmaceuticals Inc (PCRX)’s stock declined 27.90%. The Pointstate Capital Lp holds 1.19M shares with $54.37 million value, up from 1.14 million last quarter. Pacira Pharmaceuticals Inc now has $1.46 billion valuation. It closed at $35.75 lastly. It is down 33.05% since April 17, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.

Pointstate Capital Lp decreased Array Biopharma Inc (NASDAQ:ARRY) stake by 1.48M shares to 409,800 valued at $5.25M in 2017Q4. It also reduced Boeing Co (NYSE:BA) stake by 159,414 shares and now owns 970,086 shares. Dynavax Technologies Corp (NASDAQ:DVAX) was reduced too.

Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pacira Pharmaceuticals had 103 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Mizuho on Tuesday, July 25 with “Buy”. The company was maintained on Wednesday, August 2 by Piper Jaffray. The rating was downgraded by Brean Capital to “Hold” on Friday, July 1. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Hold” rating given on Tuesday, February 13 by Mizuho. Canaccord Genuity downgraded Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, October 30 to “Hold” rating. Janney Capital maintained the stock with “Neutral” rating in Friday, December 30 report. On Wednesday, March 22 the stock rating was maintained by Wedbush with “Outperform”. The company was maintained on Monday, November 20 by Wedbush. The firm earned “Buy” rating on Thursday, January 4 by H.C. Wainwright. Canaccord Genuity maintained the stock with “Buy” rating in Monday, May 29 report.

Investors sentiment increased to 1.4 in 2017 Q4. Its up 0.01, from 1.39 in 2017Q3. It is positive, as 29 investors sold PCRX shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported. Voya Invest Mngmt Limited Liability Corporation owns 0.06% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 588,447 shares. 1,914 are owned by Sei Invs. Opus Point Ptnrs Mgmt Ltd invested 0.99% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Pnc Financial Svcs Group Inc holds 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 7,819 shares. Principal Group Inc Inc owns 11,236 shares or 0% of their US portfolio. Manufacturers Life Ins The owns 30,013 shares. Tiaa Cref Mgmt Ltd Liability has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 195,516 shares. Goldman Sachs Grp Inc owns 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 143,933 shares. Alyeska Inv Grp Inc Ltd Partnership holds 1.02M shares. Plante Moran Ltd owns 428 shares. 11,700 were accumulated by Cornerstone Mngmt Holdings Ltd Liability Company. International Gp Inc holds 26,470 shares. Art Advsr Ltd Llc holds 0.02% or 8,300 shares. Kennedy Capital Management Inc reported 0.08% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Schroder Mngmt Grp reported 0.07% stake.

Since December 15, 2017, it had 0 buys, and 2 sales for $1.18 million activity. 340 shares valued at $14,858 were sold by Riker Lauren Bullaro on Friday, December 15. Another trade for 28,885 shares valued at $1.16M was made by STACK DAVID M on Wednesday, January 10.

Among 8 analysts covering Endeavour Silver Corp (NYSE:EXK), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Endeavour Silver Corp had 32 analyst reports since August 24, 2015 according to SRatingsIntel. The company was upgraded on Monday, August 24 by Zacks. The stock of Endeavour Silver Corp. (NYSE:EXK) has “Buy” rating given on Friday, April 7 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Friday, August 4 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, October 25. On Friday, November 17 the stock rating was initiated by BMO Capital Markets with “Market Perform”. The firm has “Buy” rating given on Wednesday, October 11 by Noble Financial. IBC downgraded the shares of EXK in report on Tuesday, February 23 to “Underperformer” rating. The rating was maintained by Noble Financial on Wednesday, June 7 with “Buy”. The rating was maintained by Noble Financial with “Buy” on Friday, November 3. Noble Financial maintained the stock with “Buy” rating in Friday, August 4 report.

Endeavour Silver Corp., a mid-tier precious metals mining company, engages in evaluation, acquisition, exploration, development, extraction, processing, refining, and reclamation of silver mining properties in Mexico and Chile. The company has market cap of $365.08 million. The firm also explores for gold deposits. It has a 39.08 P/E ratio. It holds interest in the Guanaceví mine in the Durango state; and the Bolañitos and El Cubo mines in the Guanajuato state of Mexico.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Steve Bissell

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: